Literature DB >> 7401847

Wegener's granulomatosis.

A D Kornblut, S M Wolff, H O deFries, A S Fauci.   

Abstract

Wegener's granulomatosis is characterized by a necrotizing granulomatous vasculitis which can be found in both the upper and lower respiratory tracts and with either focal or proliferative glomerulonephritis. However, any organ system can be affected by the disease. Over the past 17 years, 47 patients with histologically proven Wegener's granulomatosis have been treated at the National Institute of Allergy and Infectious Disease. Since 1972, patients with head and neck manifestations have been managed in collaboration with the Department of Otolaryngology, National Naval Medical Center. Experiences with these patients have shown that all have had some degree of respiratory tract involvement, with 42/47 having disease in the nose or paranasal sinuses. An effective therapeutic regimen is possible with immunosuppressants (particularly cyclophosphamide) and locally supportive measures. As a result of such therapy, more than 80% of the patients treated have experienced long-term remissions. The clinical implications of this therapy are discussed, and a protocol for patient management presented.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7401847     DOI: 10.1288/00005537-198009000-00005

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

Review 1.  Wegener's granulomatosis. Thoughts and observations of a pathologist.

Authors:  F Wegener
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

2.  Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener's).

Authors:  Marcos Martinez Del Pero; Niels Rasmussen; Afzal Chaudhry; Piyush Jani; David Jayne
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-18       Impact factor: 2.503

3.  Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes.

Authors:  Mara Felicetti; Diego Cazzador; Roberto Padoan; Alfonso Luca Pendolino; Chiara Faccioli; Ennio Nardello; Alvise Berti; Marina Silvestrini; Giuseppe Paolazzi; Giuliano Brunori; Elisabetta Zanoletti; Enzo Emanuelli; Alessandro Martini; Franco Schiavon
Journal:  Clin Rheumatol       Date:  2018-02-20       Impact factor: 2.980

Review 4.  Clinic manifestations in granulomatosis with polyangiitis.

Authors:  A Greco; C Marinelli; M Fusconi; G F Macri; A Gallo; A De Virgilio; G Zambetti; M de Vincentiis
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.